Procoagulant state in heart failure with preserved left ventricular ejection fraction

International Heart Journal

Volumn 50, Issue 5, 2009, Pages 591-600

  Jug, Borut ^a   Vene, Nina ^a   Salobir, Barbara Gužič ^a   Šebeštjen, Miran ^a   Šabovič, Mišo ^a   Keber, Irena ^a  

^a UNIVERSITY MEDICAL CENTRE LJUBLJANA   (Slovenia)

Author keywords

Biological markers; Blood coagulation; Diastolic; Fibrin fragment D dimer; Heart failure; Plasminogen activator inhibitor; Tissue plasminogen activator

Indexed keywords

BRAIN NATRIURETIC PEPTIDE; D DIMER; PLASMINOGEN ACTIVATOR INHIBITOR; TISSUE PLASMINOGEN ACTIVATOR;

ADULT; AGED; ARTICLE; BLOOD CLOTTING; CONTROLLED STUDY; FEMALE; FIBRINOLYSIS; HEART FAILURE; HEART LEFT VENTRICLE EJECTION FRACTION; HEART LEFT VENTRICLE FUNCTION; HEMOSTASIS; HUMAN; MAJOR CLINICAL STUDY; MALE; OUTPATIENT; PRIORITY JOURNAL; SYSTOLIC DYSFUNCTION;

AGED; FEMALE; FIBRIN FIBRINOGEN DEGRADATION PRODUCTS; HEART FAILURE; HEMOSTASIS; HUMANS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; NATRIURETIC PEPTIDE, BRAIN; PEPTIDE FRAGMENTS; PLASMINOGEN INACTIVATORS; STROKE VOLUME; TISSUE PLASMINOGEN ACTIVATOR; VENTRICULAR DYSFUNCTION, LEFT;

EID: 74849085512     PISSN: 13492365     EISSN: 13493299     Source Type: Journal    
DOI: 10.1536/ihj.50.591     Document Type: Article

References (37)

1. Lip GY, Gibbs CR. Does heart failure confer a hypercoagulable state? Virchow's triad revisited J Am Coll Cardiol 1999; 33: 1424-6. (Review)
2. Davis CJ, Gurbel PA, Gattis WA, et al. Hemostatic abnormalities in patients with congestive heart failure: diagnostic significance and clinical challenge. Int J Cardiol 2000; 75(1): 15-21. (Review)
3. Hobbs RB, Hampton B. Heart failure and venous thromboembolism: A major hidden risk. Br J Cardiol 2004; 11(1):27-32.
4. Howell MD, Geraci JM, Knowlton AA. Congestive heart failure and outpatient risk of venous thromboembolism: a retrospective, case-control study. J Clin Epidemiol 2001; 54: 810-6.
5. Dunkman WB. Thromboembolism and antithrombotic therapy in congestive heart failure. J Cardiovasc Risk 1995; 2: 107-17. (Review)
6. Loh E, Sutton MS, Wun CC, et al. Ventricular dysfunction and the risk of stroke after myocardial infarction. New Engl J Med 1997; 336: 251-7.
7. Jafri SM. Hypercoagulability in heart failure. Semin Thromb Hemost 1997; 23: 543-5. (Review)
8. Keber I, Keber D, Stegnar M, Vene N. Tissue plasminogen activator release in chronic venous hypertension due to heart failure. Thromb Haemos 1992; 68: 321-4.
9. Owan TE, Hodge DO, Herges RM, Jacobsen SJ, Roger VL, Redfield MM. Trends in prevalence and outcome of heart failure with preserved ejection fraction. N Engl J Med 2006; 355: 251-9.
10. Lip GY, Lowe GD, Metcalfe M, Rumley A, Dunn FG. Is diastolic dysfunction associated with thrombogenesis? A study of circulating markers of a prothrombotic state in patients with coronary artery disease. Int J Cardiol 1995; 50; 31-42.
11. Lee KW, Blann AD, Lip GY. Impaired tissue Doppler diastolic function in patients with coronary artery disease: relationship to endothelial damage/dysfunction and platelet activation. Am Heart J 2005; 150(4): 756-66.
12. Paulus WJ, Tschöpe C, Sanderson JE, et al. How to diagnose diastolic heart failure: a consensus statement on the diagnosis of heart failure with normal left ventricular ejection fraction by the Heart Failure and Echocardiography Associations of the European Society of Cardiology. Eur Heart J 2007; 28: 2539-50.
13. Lip GY, Lowe GD, Metcalfe MJ, Rumley A, Dunn FG. Effects of warfarin therapy on plasma fibrinogen, von Willenbrand factor, and fibrin D-dimer in left ventricular dysfunction secondary to coronary artery disease with and without aneurysms. Am J Cardiol 1995; 76: 453-8.
14. Chin BS, Conway DS, Chung NA, Blann AD, Gibbs CR, Lip GY. Interleukin-6, tissue factor and von Willenbrand factor in acute decompensated heart failure: relationship to treatment and prognosis. Blood Coagul Fibrinolysis 2003; 14: 515-21.
15. Chong AY, Lip GY. Viewpoint: the prothrombotic state in heart failure: a maladaptive inflammatory response? Eur J Heart Fail 2007; 9: 124-8. (Review)
16. Vaughan DE, Lazos SA, Tong K. Angiotensin II regulates the expression of plasminogen activator inhibitor-1 in cultured endothelial cells. A potential link between the renin-angiotensin system and thrombosis. J Clin Invest 1995; 95: 995-1001.
17. Preckel D, von Känel R. Regulation of Hemostasis by the Sympathetic Nervous System: Any Contribution to Coronary Artery Disease? Heartdrug 2004; 4: 123-30.
18. Cugno M, Mari D, Meroni PL, et al. Haemostatic and inflammatory biomarkers in advanced heart failure: role of oral anticoagulants and successful heart transplantation. Br J Haematol 2004; 126(1): 85-92.
19. Danenberg HD, Szalai AJ, Swaminathan RV, et al. Increased thrombosis after arterial injury in human C-reactive protein-transgenic mice. Circulation 2003; 108: 512-5.
20. Devaraj S, Xu DY, Jialal I. C-reactive protein increases plasminogen activator inhibitor-1 expression and activity in human aortic endothelial cells: implications for the metabolic syndrome and athero-thrombosis. Circulation 2003; 107: 398-404.
21. Conway DS, Buggins P. Hughes E, Lip GY. Relationship of interleukin-6 and C-reactive protein to the prothrombotic state in chronic atrial fibrillation. J Am Coll Cardiol 2004; 43(11): 2075-82.
22. Sbarouni E, Bradshaw A, Andreotti F, Tuddenham E, Oakley CM, Cleland JG. Relationship between hemostatic abnormalities and neuroendocrine activity in heart failure. Am Heart J 1994; 127: 607-12.
23. Gibbs CR, Blann AD, Watson RDS, Lip GY. Abnormalities of hemorheological, endothelial, and platelet function in patients with chronic heat failure in sinus rhythm: effects of angiotensin - converting enzyme inhibitor and beta-blocker therapy. Circulation 2001; 103: 1746-51.
24. Kothari SA, Le MK, Ghandhi PJ. Effects of angiotensin converting enzyme inhibitors on thrombotic mediators: potential clinical implications. J Thromb Thrombolysis 2003; 15: 217-25. (Review)
25. Labinjoh C, Newby DE, Pellegrini MP, Johnston NR, Boon NA, Webb DJ. Potentiation of bradykinin-induced tissue plasminogen activator release by angiotensin-converting enzyme inhibition. J Am Coll Cardiol 2001; 38: 1402-8.
26. Yip HK, Chang LT, Sun CK, et al. Platelet activation in patients with chronic nonvalvular atrial fibrilation. Int Heart J 2006; 47: 371-9.
27. Ozdeznir N, Kaymaz C, Daglar E, Karakaya O, Akçay M, Ozkan M. Severe mitral regurgitation may prevent mural thrombus formation within the left ventricle with systolic dysfunction. Jpn Heart J 2002; 43: 495-503.
28. Bilge M, Eryonucu B, Güler N, Erkoç R. Right atrial appendage function in patients with chronic nonvalvular atrial fibrillation. Jpn Heart J 2000; 41: 451-62.
29. Singer DE, Albers GW, Dalen JE, et al. Antithrombotic therapy in atrial fibrillation: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest 2008; 133: 546S-92.
30. Heart Failure Society Of America. HFSA 2006 Comprehensive Heart Failure Practice Guideline. J Card Fail 2006; 12: e1-2.
31. Task Force for Diagnosis and Treatment of Acute and Chronic Heart Failure 2008 of European Society of Cardiology. ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2008: the Task Force for Use Diagnosis and Treatment of Acute and Chronic Heart Failure 2008 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association of the ESC (HFA) and endorsed by the European Society of Intensive Care Medicine (ESICM). Eur Heart J 2008;29: 2388-442. (Review)
32. Guo GB, Chang HW, Chen MC, Yang CH. Underutilization of anticoagulation therapy in chronic atrial fibrillation. Jpn Heart J 2001; 42: 55-65.
33. Lip GY, Blann AD. Does hypertension confer a prothrombotic state? Virchow's triad rivisited. Circulation 2000; 101: 218-20.
34. Lip GY, Blann AD, Beevers DG. Prothrombotic factors, endothelial function and left ventricular hypestrophy in isolated systolic hypertension compared to systolic-diastolic hypertension. J Hypertens 1999; 17: 1203-7.
35. Lip GY, Blann AD, Jones AF, Lip PL, Beevers DG. Relation of endothelium, thrombogenesis, and hemorheology in systemic hypertension to ethnicity and left ventricular hypertrophy. Am J Cardiol 1997; 80: 1566-71.
36. Sechi LA, Zingaro L, Catena C, Casaccio D, De Marchi S. Relationship of fibrinogen levels and hemostatic abnormalities with organ damange in hypertension. Hypertension 2000; 36: 978-85.
37. Brown N, Vaughan D. Role of angiotensin II in coagulation and fibrinolysis. Heart Fail Rev 1999: 193-8.